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Emergmg trends in invasive candidiasis are notable for a dramatic increase in infections due to non-albicans 
Candida species. An increasing number of immunocompromised patients at risk from fungal infections, an 
overall greater acuity of illness in the hospitalized patients, particularly those in the critical care units, escalating 
rates of broad-spectrum antibiotic usage, and wide utilization of azoles as prophylaxis have probably 
contributed towards the changing epidemiology of invasive candidiasis. Given the inherent decreased 
susceptibility of many of the non-albicans Candida species to currently available antifungal agents, these 
evolving trends have far-reaching clinical relevance. 
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INTRODU CTl ON 
Increasingly recopzed as a significant human pathogen 
within the last two decades, Candida species have now 
emerged as one of the leading causes of nosocomial blood- 
stream infections Overall, 86% of a l l  nosocomial fungal 
infections and 8-10% of the nosocomial bloodstream infec- 
tions have been shown to be due to Candida species [1,2]. 
Indeed, Candida species are the fourth most commonly 
recovered isolate in blood cultures in the US [3]. Mortality 
rates associated with candidemia have been reported to range 
between 38-75% [4]. Candidemia has been shown to be an 
independent determinant of mortality and a contributor to 
excess hospitalization and resource utilization. The excess 
hospital stay as a result of candidemia averaged 34 days in one 
study [5]. The costs per case of candidemia, attributable largely 
to prolongation of hospitalization, ranged between US$34 123 
and $44 536 [5]. 
Within the past decade, the proportion of infections caused 
by non-albicans Candida species has increased exponentially 
(Table 1). Nearly one-half, and up to 63-88% of the cases of 
hematogenous candidiasis are now reported to be the result of 
Candida species other than albicans [6-lo]. Given the inherent 
decreased susceptibility of many of non-albicans Candida 
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species to currently available antifungal agents, these emerging 
trends have far-reaching clinical relevance. This review focuses 
on the changmg epidemiology of Candida infections in various 
hosts, virulence, clinical characteristics, and antifungal suscept- 
ibilities of the emerging Candida spp., and therapeutic 
implications of these trends in the management of infections 
that result from Candida spp. 
EVOLVING TRENDS IN THE EPIDEMIOLOGY OF INVASIVE 
CAN DlDlASlS 
Although controversial, utilization of azoles has been proposed 
to be a significant variable contributing towards the changing 
epidemiology of invasive candidasis. An overall trend towards 
an increase in the proportion of infections due to non-albicans 
Candida species, particularly C.  kmsei and glabrata, has been 
shown to correlate temporally with azole usage in a number of 
reports [6,7,11-141. In a multicenter study conducted between 
1990 and 1994, the frequency of candidemia resulting from 
non-albicans species increased significantly through the study 
period [ l  11. Non-albicans Candida species increased from 40 
to 53% of all candidemias and surpassed C. albicans in 
frequency towards the end of the study [Ill. Candidemia 
occuring during fluconazole therapy was more likely to be due 
to non-albicans species than C. albicalzr [ll].  Longitudinal 
assessment of nosocomial surveillance data from 1981 through 
1993 at a primary and tertiary care medical center in Taiwan 
showed that the proportion of fungemias due to C.  glubrutu and 
C. parapriloris had increased four-and six-fold, respectively; the 
consumption of azoles at this institution had increased rapidly 
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Table 1 Global trends in frequency and species distribution for invasive Candidiasis 
Study 
Ref. periods Country 
[61 1988-92 USA 
[71 1 981 -93 Taiwan 
[81 1995-96 Brazil 
[46] 1988-97 Italy 





997-98 USA, Canada 
and Latin 
America 
[21] 1994 Israel 
[49] 1992-94 Europe and 
Middle East 
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Patient Incidence of 
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*The values represent the rate in 1993. 
**The values represent the rate from 1991 to 1995. 
since 1991 [7]. Global trends in the frequency and species 
distribution for invasive candidiasis are summarized in Table 1. 
Candida infections in intensive care units 
Major changes in the demographic characteristics and an 
overall greater acuity of dlness have been documented in 
hospitalized patients in recent years. The National Nosocomial 
Infection Surveillance Program has documented that, while 
the total number of hospital beds in US hospitals decreased, 
the relative number of intensive care unit (ICU) beds 
increased significantly between 1988 and 1995 [15]. Con- 
currently, advances in supportive medical care have led to 
improved survival and prolonged ICU stay in critically ill 
patients, rendering them susceptible to nosocomial infections. 
Risk factors for candidemia, such as broad-spectrum antibiotic 
usage, serious underlymg medical conditions and the use of 
invasive devices, including intravascular catheters, are widely 
prevalent in ICU patients. It is, therefore, not surprising that 
ICUs have emerged as epicenters for nosocomial fungal 
infections such as candidemia. The National Nosocomial 
Infection Surveillance Program documented a doubling in the 
rate of nosocomial fungal infections between 1980 and 1990, 
with the greatest increase (124%) occurring in the surgical 
patients El]. In another study, the overall fungal infection rate 
increased fiom 0.9 infections per 1000 discharges in 1981 to 
6.6 per 1000 discharges in 1993, with the highest rate reported 
in the medical ICU (26.5 per 1000 discharges) [7]. Indeed, 25- 
50% of the nosocomial bloodstream infections due to Cundidu 
have now been reported to occur in critical care units [4]. 
The proportion of nosocomial candidemias occurring in the 
intensive-care setting, however, is influenced by the specific 
patient population being cared for in that institution. In an 
oncology center, 75% of the hematogenous Cundidu infections 
occurred outside the ICU [6]. 
Azole (fluconazole) usage in ICUs also steadily increased in 
the 1990s [16]. A vast proportion of the azole utilization in this 
setting is not for the treatment of documented infections. In 
the surgical unit of a university hospital, 73% of the patients 
who received fluconazole were treated prophylactically or 
empirically [16]. Non-albicans Candida species particularly C. 
glubruta, have emerged as important nosocomial pathogens at 
these centers [16,17]. 
Candidemia in the neonatal units 
Candida sp. are being recopzed  as increasingly important 
nosocomial pathogens in neonatal ICUs. Innate characteristics 
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of the pretenn infants that predispose them to invasive fungal 
infections include the relative immaturity of the immune 
system, prolonged hospitalization, indwelling catheters, par- 
enteral intralipids, immature skin structure, and disruption of 
cutaneous barriers [18-201. Nosocomial outbreaks and 
transmission, particularly of C. parapsilosis and C. lusitaniae 
via the hands of health-care workers, also represent a major 
source of acquisition of Candida infection in this setting [19]. 
In a survey of hospital-based infectious disease units, the 
incidence of candidemia in preterm units was 18-fold hgher 
than in the surgical ward, and 1.4-fold higher than in the adult 
ICU 1211. Overall trends are noteworthy for a rise in the rate 
of candidemia in these patients as well. Between 1981 and 
1995, an increase in the incidence of candidemia was 
documented to be more than 11-fold in a neonatal ICU 
12.01. The prevalent Candida species has been documented to 
shift fiom C. albicans to C. parapsilosis [20]. However, 
candidemia due to C. parapsilosis has been associated with 
lower mortality than other Candida spp. 
Candidemia in patients with hematological malignancies and 
hematopoeitic stem cell transplant recipients 
Trends in invasive candidiasis in hematopoeitic stem cell 
transplant recipients are notable for a decrease in the fkequency 
and overall mortality associated with candidemia, but a shift in 
the species of Candida towards non-albicans species [12]. 
Between 1988 and 1992, a relative decrease in the incidence of 
C.  albicans and C. tropicalis and an increase in C. h s e i  and C. 
glabrata was documented [6]. Fluconazole prophylaxis was 
independently associated with protection against the develop- 
ment of C. tropicalis (odds ratio 0.08) and C. albicans (odds ratio 
0.15) and was the most important determinant for the relative 
increase in C. krusei (odds ratio 27.07) and C. glabrata (odds 
ratio 5.08) at that institution [6]. Prophylaxis with fluconazole, 
employed from the receipt of conditioning chemotherapy 
until 75 days after bone marrow transplantation, led to a 
decline in the incidence of candidemia from 11.9% to 4.6% 
[12]. The predominant pathogens, however, changed tiom C. 
dbicans and C. tropicalis to C. glabrata and C. krusei. At an 
oncology center in Europe, the use of flucomzole prophylaxis 
and eventually its replacement with oral amphotericin B 
corresponded to an increase and then to a decrease, 
respectively, in the incidence of C. krusei fungemia [9]. 
Centers ut&zing fiuuconazole prophylaxis have also docu- 
mented an evolution in the risk factors for the development of 
candidemia [12]. Traditional risk factors, such as acute graft vs. 
host disease, neutropenia and receipt of corticosteroids, and 
total body irradiation were less s i d c a n t  predictors of 
candidemia in patients receiving fluconazole [22]. Instead, 
bacteremia, receipt of quinolones, and cytomegalovirus ‘disease 
were significant predictors of candidemia in this study 1221. It 
remains to be determined if this association reflects the effect 
of quinolones in promoting fungal colonization, or as yet 
unrecognized effects of the aforementioned variables on fungal 
pathogenicity. 
An intriguing observation, largely paralleling a decline in 
the incidence of candidemia, is a rise in the frequency of 
Aspergillus and other mold infections in patients with 
hematological malignancies. At a large US bone marrow 
transplant center, the 1-year cumulative incidence of invasive 
aspergdlosis increased fiom 7.3% in 1992 to 16.9% in 1998 
[12]. Similar data have begun to emerge fiom other centers 
[23]. A number of factors, such as an increasing number of 
immunosuppressed hosts, advances in laboratory technology 
for identification of mycelial fungi and changes in transplanta- 
tion practices (such as the introduction of peripheral blood 
cells as a source of stem cells, and CD34-selected stem cells for 
transplantation) could have accounted for the observed rise in 
invasive mold infections. It is also plausible that current 
antifungal prophylactic practices could be contributing 
towards these trends. Aspgillus and other mold infections 
were documented in 29% of bone marrow transplant 
recipients receiving fluconazole prophylaxis as compared with 
18% in those without fluconazole in another report fiom this 
institution; the use of fluconazole approached statistical 
sigmficance as an independent risk factor for invasive mold 
infections [24). Thus, the potential for selecting fun@ innately 
resistant to fluconazole or overcoming ‘colonization resistance’ 
with fluconazole cannot be completely excluded. 
Emerging data also suggest that prophylactic strategies 
against other opportunistic pathogens, such as cytomegalo- 
virus, may also be contributing towards the changing 
epidemiology of invasive mycoses in transplant recipients. 
Prophylaxis for cytomegalovirus with ganciclovir (often 
continued for up to 3 months post-transplantation) is now 
routinely employed in bone marrow transplant recipients. A 
strilung observation has been that the duration of ganciclovir 
correlated independently with a higher risk for invasive 
aspergillosis; each week of ganciclovir treatment beyond 4 
weeks increased the risk of invasive aspergdosis by a factor of 
1.4 [ZS]. The evolving trends in fungal infections in bone 
marrow transplant recipients therefore probabIy represents the 
cumulative effect of a number of interrelated factors. 
lnvasive candidiasis in organ transplant recipients 
The impact of invasive candidiasis in organ transplant 
recipients is greatest in the context of liver and pancreas 
transplant recipients. Temporal trends in invasive fungal 
infections are notable for an overall decline in the incidence 
of invasive candidiasis in liver transplant recipients. Whereas in 
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earlier studies in liver transplant recipients invasive candidiasis 
was documented in 16-30% of the patients, more recently, 
many transplant centers have reported an incidence lower than 
lo%, even in the absence of systemic antifungal prophylaxis 
[26]. A conservative approach towards immunosuppression 
but, more importantly, refinement and surgcal technologcal 
advances, may have led to a decrease in putative risk factors 
and, consequently, in the rate of invasive candidiasis. In a study 
in liver transplant recipients, the incidence of invasive fungal 
infections declined from 18% between 1983 and 1992, to 9% 
between 1993 and 1997 [27]. Renal failure, transfusion 
requirements, retransplantation, choledochocholejejunostomy 
and fungal colonization were identified as significant risk 
factors for invasive fungal infections. A total of 82% of patients 
prior to 1992, but only 10% since 1992 exhibited two or 
more of the aforementioned risk factors for invasive fungal 
infections [27]. 
The incidence of invasive aspergdiosis and mold infections, 
however, not only remains unchanged but may indeed be 
increasing in organ transplant recipients. In a prospective 
study, fungi other than Aspergillus accounted for 37% of all 
mold infections and for 43% of the deaths in organ transplant 
recipients with mold infections [28]. 
CLINICAL CORRELATES AND ANTIFUNGAL 
SUSCEPTIBILITIES OF THE EMERGING CANDlDA SPECIES 
C. albicans has long been the predominant Candida species 
associated with infections. It is also among the most virulent of 
Candida species. Although the potential to develop azole 
resistance has been documented, C. albicans is generally 
susceptible to all the antifungal agents. O f  the non-albicans 
Candida species, C. tropicalis and C. glabrata are encountered 
most frequently. C.  tropicalis is the most virulent and more 
likely to occur in neutropenic patients. Patients with 
hematologcal malignancies who developed C. tropicalis 
fungemia, had hgher APACHE 111 scores [6]. Infections due 
to C. tropicalis have been shown to occur earlier during 
hospitalization than other Candida species. C. tropicalis is 
generally susceptible to azoles, but the MICs for fluconazole 
are higher than for C. albicans. Patients with C. glabrata 
infections are generally severely debilitated or immunocom- 
promised hosts. Although relatively less virulent, C. glabrata 
was associated with the highest rate of nonocular complica- 
tions in patients with candldemia, such as endocarditis, 
osteomyelitis and abscesses [ l l ] .  This species is innately more 
resistant to antifungal agents, particularly the azoles, with 
MICs that are between 16 and 64 times higher than those for 
C. albicans. 
Infections due to C. parapsilosis have been shown to 
correlate strongly with the presence of a central venous 
catheter and the use of total parented nutrition [29]. C. 
parapsilosis is a fiequent colonizer of the skin; outbreaks of C. 
parapsihis have been linked to cross-transmission via the hands 
of the health-care providers [19]. C. parapsilosis also possesses 
the ability to form slime, which enhances its adherence to 
synthetic material and plastic tubing. These characteristics 
likely account for its observed association with catheter-related 
infections. C. parapsilosix is considered to be less virulent and is 
associated with lower mortality rates as compared to other 
Candida species. 
C. kmsei is intrinsically resistant to fluconazole. Infections 
with C .  kvusei are strongly associated with prior fluconazole 
prophylaxis and neutropenia. C. lusitaniae, accounting for 1- 
2% of the candidemias, i s  susceptible to azoles, but has innately 
higher MICs to amphotericin B. Amongst less fiequently 
encountered species of Candida is C. guillermondii. A predilec- 
tion to involve neutropenic patients has been noted for C. 
guillwmondii [30]. In bone marrow transplant recipients, C. 
guillemondii caused 3% of the candidemias and was fluconazole 
resistant in all cases [12]. In 5/9 cancer patients, C. guillermondii 
fungemias occured as a breakthrough infection in patients 
receiving antifungal agents [30]. The newly described species 
C. dubliniensis has so far been recovered primarily &om oral 
candidiasis lesions in HIV-infected patients. However, candi- 
demia due to C. dubliniensis has recently been described in 
bone marrow transplant and neutropenic patients [31]. C. 
dubliniensis as C. albicans produces germ tubes and chlamydos- 
pores. Fluconazole may be less active against C. dubliniensis as 
compared with C .  albicans. 
TREATMENT OF HEMATOGENOUS CANDlDlASlS 
O f  antifungal agents currently available for the treatment of 
Candida infections, amphotericin B is fungicidal, whereas 
azoles have fungistatic activity. However, two randomized 
controlled trials in non-neutropenic patients [32,33] and two 
large observational studies that included neutropenic and 
immunocompromised hosts [34,35] have documented that 
fluconazole at a dosage of 400 mg per day was comparable in 
efficacy with amphotericin B for the treatment of candidemia. 
The choice of antifingal agent depends on the clinical status of 
the patient, the Candida species detected (or antifungal 
susceptibility, if known), and whether the patient had 
previously been treated or had received prophylaxis with an 
azole. In patients deemed to be clinically stable, i.e. those who 
do not have hypotension and whose overall condition is not 
considered to be worsening, initial therapy with fluconazole is 
reasonable [36]. In clinically unstable patients and those who 
may have previously been in receipt of the azole, amphotericin 
B at a dosage of 20.7 mg/kg per day should be considered 
until the pathogenic species is known [36]. 
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Although there may be exceptions, knowledge of Candida  
species can guide subsequent antifungal drug treatment. Given 
that C. krusei is inherently resistant to fluconazole and may 
have reduced susceptibility to amphotericin B, amphotericin B 
at a dosage of 1.0 mg/kg per day is recommended for the 
treatment of C. krusei infections. C. glabrata may also be 
relatively resistant to fluconazole; 15% of the bloodstream 
isolates in a recent study were resistant to fluconazole [37]. 
Although fluconazole at dosages of 800 mg per day may be 
considered, particularly in stable patients, most authorities 
recommend amphotericin B for the treatment of C. glabrata 
fungemia. C. lusitaniae is resistant to amphotericin B; 
fluconazole therefore is the therapy of choice for this species. 
C. albicans, C. tropicalis and C. parapsilais are generally 
susceptible to fluconazole; treatment either with fluconazole or 
amphotericin B is considered acceptable. At the current time, 
liposomal preparations ofamphotericin B should be reserved for 
the treatment of canddemia in patients intolerant or reeactory 
to the aforementioned antifungal agents. The treatment guide- 
lines for Infectious Diseases Society ofAmerica recommend that 
the therapy for canhdemia should be continued for 2 weeks 
beyond the last positive blood culture or until resolution of the 
clinical manifestations of infections [36]. 
A controversial issue pertaining to the management of 
canhdemia is whether the indwelling catheters should be 
removed. In hematologcal patients with neutropenia and 
bone marrow transplant recipients, most candidemias result 
from endogenous gastrointestinal tract colonization and 
subsequent dissemination. Routine catheter removal is of 
unproven e6cacy in this setting and, therefore, is debatable. 
An exception is fungemia resulting from C. parapsilosis, which 
is frequently catheter related and not associated with previous 
colonization. For non-neutropenic patients, catheter removal 
is strongly recommended. 
Hematopoietic factors such as granulocyte (G-CSF) and 
granulocyte-macrophage colony stimulating factor (GM-CSF) 
have been shown not only to accelerate the resolution of 
neutropenia, but also to enhance the activity of neutropl-nls 
against Candida. Clinical trials documenting the efficacy of 
cytokines and other immunomodulatory agents for the 
management of invasive canhdiasis, are largely lacking. 
However, the American Society of Clinical Oncology has 
recommended that G-CSF and GM-CSF be administered to 
adults and children with febrile neutropenia for whom the 
probability of infection is 2 40% 1381. 
PROPHYLAXlS FOR INWASWE CANDlDlASlS 
Randomized, controlled trials in bone marrow transplant 
recipients have documented that fluconazole at a dosage of 
400 mg per day was efficacious as prophylaxis for fungal 
infections [39,40]. Fluconazole was utilized during the period 
of neutropenia in one [39] and during the neutropenia and 
acute graft-os.-host disease (75 days after bone marrow 
transplantation) in the other [40]. While both studies showed 
a reduction in superficial and invasive fungal infections, a 
decrease in mortality was documented only in one [40]. Long- 
term (8 years) follow-up of the second study showed a 
significant survival benefit in the fluconazole recipients, as 
compared with the placebo recipients [12]. Significantly more 
patients who received placebo died with candidiasis, early 
(I" 0.001) and late ( P =  0.006), after bone marrow transplan- 
tation [12]. The study also showed that fewer patients who 
received fluconazole developed acute graft-ox.-host disease 
involving the gastrointestinal tract. These data support the 
utilization of antifungal prophylaxis with fluconazole in 
neutropenic patients and high-risk bone marrow transplant 
recipients. However, a higher risk of azole-resistant candidiasis 
and possibly aspergdlosis should be borne in mind. 
Unlike bone marrow transplant recipients, a reduction in 
mortahty with fluconazole prophylaxis has never been 
documented in a randomized trial in liver transplant recipients. 
The need for fluconazole prophylaxis in these patients should, 
therefore, be assessed based on the institutional trends in the 
incidence of invasive candihasis and should be targeted 
towards high-risk patients previously defined [41]. Flucona- 
zole prophylaxis has been reported to be effective after 
pancreas transplantation [42,43]. Given the significant mor- 
bidity and adverse effect on patient outcome that are associated 
with Candida  infections, prophylaxis with fluconazole may be 
considered for high-risk pancreas transplant recipients [41 J .  
FUTURE DIRECTIONS 
The increasing importance of antifungal resistance in Candida  
underscores the need for the development of antifungal agents 
with alternative mechanisms of action and lesser toxicity. Of 
drugs currently in trials, echmocandins have unique char- 
acteristics that render them potentially suitable drugs against 
Candida  species, including azole-resistant candidiasis. These 
drugs impair glucan synthesis and are fungicidal against a 
number of pathogenic fungi including Candida  species. Novel 
classes of antifungal agents, e.g. the cationic peptide histatin 
represent potential therapeutic strategies in the future [44,45]. 
The emergence of non-albicans Candida species as significant 
pathogens also suggests that access to antifungal susceptibility 
testing may need to be more widely available. 
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